Acalaside 100mg Capsule

Acalaside100mg capsule is used in the treatment of mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma. It contains an active ingredient of Acalabrutinib which belongs to the class of Tyrosine kinase inhibitors. The medicine works by blocking Bruton’s tyrosine kinase (BTK) that help the cancerous B cells to grow and survive, it slows down the growth or stop the growth of cancer cells in the body. Doctors prescribed this medication as a part of targeted therapy for blood cancer to control the disease and improve patient outcomes.

Mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma

Medications show various side effects depending on how an individual’s body responds to the treatment. Consult the doctor if any of the symptoms persist while using Acalaside 100mg capsule. Common side effects include:
● Fatigue
● Diarrhea
● Anaemia
● Upper respiratory tract infection
● Neutropenia (Low neutrophill count)
● Headache
● Musculoskeleton pain

Acalaside 100mg capsule should be taken orally; healthcare experts mostly prefer with food or between meals, it is better to take it at the fixed time everyday to enhance the effectiveness of the medication. The medicine takes several weeks to show a noticeable response so it is important to take it as prescribed and follow up regularly with the doctor.

The body contains bruton’s tyrosine kinase (BTK) which interfere with the B cell receptor signaling pathway and when they goes out of control, B cells can reproduce at an uncontrolled rate and lead to lymphoma. Acalaside 100mg capsule blocks the Bruton’s tyrosine kinase (BTK) enzyme, it helps to slow or stop the progression of cancer growth in the body.

• Wolska-Washer, A., & Robak, T. (2022). Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology, 15(3), 183-194.
• Byrd, J. C., Wierda, W. G., Schuh, A., Devereux, S., Chaves, J. M., Brown, J. R., ... & Furman, R. R. (2020). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, The Journal of the American Society of Hematology, 135(15), 1204-1213.
• Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., ... & Jurczak, W. (2018). Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. The Lancet, 391(10121), 659-667.
• Awan, F. T., Schuh, A., Brown, J. R., Furman, R. R., Pagel, J. M., Hillmen, P., ... & Byrd, J. C. (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood advances, 3(9), 1553-1562.
• Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O’Brien, S., Brown, J. R., ... & Wierda, W. G. (2021). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 137(24), 3327-3338.